Valuation : Laboratorios Richmond S.A.C.I.F.

Market Cap 128B 84.93M 73.08M 68.76M 62.81M 117M 8.02B 118M 812M 315M 4.11B 319M 312M 13.25B P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 359B 238M 205M 193M 176M 330M 22.49B 330M 2.28B 884M 11.54B 895M 875M 37.18B EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
08-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-10 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
05-07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-09 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-05-07 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
25-03-07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-08-12 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
24-03-10 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
1 day+1.60%
1 week+0.96%
Current month-1.55%
1 month+3.26%
3 months-2.76%
6 months+1.60%
Current year-19.75%
1 week 1,530
Extreme 1530
1,615
1 month 1,495
Extreme 1495
1,615
Current year 1,420
Extreme 1420
2,130
1 year 945
Extreme 945
2,300
3 years 480.5
Extreme 480.5
2,300
5 years 215
Extreme 215
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 2025-04-28
Corporate Officer/Principal - 2025-04-28
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.60%+0.96%+38.43%+176.13% 84.93M
-0.88%-2.15%+58.05%+105.91% 1,024B
-1.15%+2.68%+54.25%+71.29% 663B
-1.44%+0.38%+20.65%+75.54% 453B
+0.14%-0.47%+30.20%+40.61% 352B
-1.33%+4.72%+24.62%+47.60% 304B
-1.15%+0.30%-0.69%+11.83% 252B
-1.55%+1.11%+54.15%+72.13% 236B
-0.88%+1.15%-14.60%-54.84% 206B
-0.15%+3.65%+31.24%+100.90% 187B
Average -0.68%+0.83%+29.63%+64.71% 367.85B
Weighted average by Cap. -0.96%+0.55%+37.63%+67.00%

Financials

2024 2025
Net sales 91.79B 60.91M 52.41M 49.31M 45.05M 84.27M 5.75B 84.5M 583M 226M 2.95B 229M 224M 9.51B 127B 84.09M 72.36M 68.08M 62.19M 116M 7.94B 117M 804M 312M 4.07B 316M 309M 13.12B
Net income 23.85B 15.82M 13.61M 12.81M 11.7M 21.89M 1.49B 21.95M 151M 58.74M 766M 59.41M 58.12M 2.47B 3.09B 2.05M 1.76M 1.66M 1.52M 2.83M 193M 2.84M 19.6M 7.61M 99.25M 7.69M 7.53M 320M
Net Debt 134B 88.68M 76.31M 71.79M 65.58M 123M 8.37B 123M 848M 329M 4.3B 333M 326M 13.84B 231B 153M 132M 124M 113M 212M 14.47B 213M 1.47B 569M 7.43B 576M 563M 23.92B
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
26-09-04 ARS 1,585.00 +1.60% 3,631
26-09-03 ARS 1,560.00 -1.58% 1,635
26-09-02 ARS 1,585.00 +2.26% 1,189
26-09-01 ARS 1,550.00 -3.73% 1,659
26-08-31 ARS 1,610.00 +2.55% 5,467
  1. Stock Market
  2. Stocks
  3. RICH Stock